[go: up one dir, main page]

CL2019003161A1 - Métodos de tratamiento selectivo del asma usando antagonistas de il-17. - Google Patents

Métodos de tratamiento selectivo del asma usando antagonistas de il-17.

Info

Publication number
CL2019003161A1
CL2019003161A1 CL2019003161A CL2019003161A CL2019003161A1 CL 2019003161 A1 CL2019003161 A1 CL 2019003161A1 CL 2019003161 A CL2019003161 A CL 2019003161A CL 2019003161 A CL2019003161 A CL 2019003161A CL 2019003161 A1 CL2019003161 A1 CL 2019003161A1
Authority
CL
Chile
Prior art keywords
antagonists
selective
treatment methods
asthma treatment
asthma
Prior art date
Application number
CL2019003161A
Other languages
English (en)
Inventor
Sarah Schmidt Grant
Shamsah Kazani
Edward Khokhlovich
Jason Laramie
Robert Martin Strieter
Tricia Ann Thornton-Wells
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2019003161A1 publication Critical patent/CL2019003161A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

LA DIVULGACIÓN SE REFIERE A MÉTODOS, REGÍMENES DE TRATAMIENTO, USOS, EQUIPOS Y TERAPIAS PARA EL TRATAMIENTO DEL ASMA, TAL COMO EL ASMA GRAVE, EMPLEANDO ANTAGONISTAS DE IL–17 EN UNA POBLACIÓN DE PACIENTES DEFINIDA POR LA CONCENTRACIÓN SÉRICA DE IGE Y, OPCIONALMENTE, TAMBIÉN UN RECUENTO DE EOSINÓFILOS EN SANGRE PERIFÉRICA.
CL2019003161A 2017-05-05 2019-11-04 Métodos de tratamiento selectivo del asma usando antagonistas de il-17. CL2019003161A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762501806P 2017-05-05 2017-05-05

Publications (1)

Publication Number Publication Date
CL2019003161A1 true CL2019003161A1 (es) 2020-02-07

Family

ID=62245372

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019003161A CL2019003161A1 (es) 2017-05-05 2019-11-04 Métodos de tratamiento selectivo del asma usando antagonistas de il-17.

Country Status (13)

Country Link
US (1) US10676522B2 (es)
EP (1) EP3619536A1 (es)
JP (1) JP2020518604A (es)
KR (1) KR20190142398A (es)
CN (1) CN110582702A (es)
AU (1) AU2018263159A1 (es)
BR (1) BR112019023141A2 (es)
CA (1) CA3062179A1 (es)
CL (1) CL2019003161A1 (es)
MX (1) MX2019013160A (es)
RU (1) RU2019139387A (es)
TW (1) TW201842933A (es)
WO (1) WO2018203289A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3689907A1 (en) * 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
EP4136110A4 (en) * 2020-04-17 2024-04-17 Eli Lilly and Company TREATMENT OF RESPIRATORY DISEASE

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0308324D0 (en) 2003-04-10 2003-05-14 Piezoptic Ltd A chemical sensing device
CN1898564A (zh) * 2003-12-24 2007-01-17 惠氏公司 治疗哮喘的方法
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
LT2481753T (lt) 2005-12-13 2018-05-25 Eli Lilly And Company Anti-il-17 antikūnai
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
NZ588853A (en) 2008-03-31 2013-07-26 Genentech Inc Compositions and methods for treating and diagnosing asthma
RU2539029C2 (ru) 2008-09-29 2015-01-10 Роше Гликарт Аг Антитела против интерлейкина 17 (ил-17) человека и их применение
EP2953969B1 (en) * 2013-02-08 2019-08-28 Novartis AG Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
CA2924873A1 (en) * 2013-10-23 2015-04-30 Genentech, Inc. Methods of diagnosing and treating eosinophilic disorders
US20160000936A1 (en) * 2014-06-10 2016-01-07 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
RS65851B1 (sr) * 2014-09-10 2024-09-30 Novartis Ag Upotreba antagonista il-17 za inhibiciju progresije strukturalnog oštećenja kod pacijenata sa psorijatičnim artritisom
GB201508832D0 (en) 2015-05-22 2015-07-01 Novartis Ag A method for detecting an analyte

Also Published As

Publication number Publication date
JP2020518604A (ja) 2020-06-25
EP3619536A1 (en) 2020-03-11
KR20190142398A (ko) 2019-12-26
RU2019139387A (ru) 2021-06-07
WO2018203289A1 (en) 2018-11-08
AU2018263159A1 (en) 2019-11-07
US10676522B2 (en) 2020-06-09
MX2019013160A (es) 2020-02-05
TW201842933A (zh) 2018-12-16
US20180319881A1 (en) 2018-11-08
BR112019023141A2 (pt) 2020-07-28
CN110582702A (zh) 2019-12-17
CA3062179A1 (en) 2018-11-08

Similar Documents

Publication Publication Date Title
CO2019011995A2 (es) Procesos para la producción de linfocitos infiltrantes de tumores y usos de ellos en inmunoterapia
MX2024013963A (es) Un antagonista de il-4r util para el tratamiento o la prevencion del asma
MX2017011834A (es) Macrociclos peptidomimeticos y usos de los mismos.
MX2019014009A (es) Metodos mejorados para la elaboracion de terapias celulares adoptivas.
DOP2017000271A (es) Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t
MX2024000348A (es) Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica.
MX2017008875A (es) Anticuerpos biespecificos contra cd3 y cd20.
CL2015002807A1 (es) Terapia de combinación
GT201700167A (es) Terapias de combinación para el tratamiento de cánceres.
MX2016005159A (es) Metodos de diagnostico y tratamiento de trastornos eosinofilicos.
MX2015010724A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MX2019008085A (es) Antagonistas de activina-actrii y usos para tratar transtornos oseos y otros.
MX370664B (es) Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos.
EA033374B1 (ru) Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения
CL2015002941A1 (es) Usos terapéuticos de empaglifozina
BR112017005598A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
AR092899A1 (es) Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
AR101476A1 (es) Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk)
MX2021008305A (es) Anticuerpos anti-cd40 para el uso en el tratamiento de hidradenitis supurativa.
UY35438A (es) Procedimiento para preparar inhibidores de la glucosilceramida sintasa.
UY34991A (es) Inhibidores de la beta-secretasa
CL2019003161A1 (es) Métodos de tratamiento selectivo del asma usando antagonistas de il-17.
MX375318B (es) Formas de dosificación y usos terapéuticos de l-4-cloro quinurenina..
MX2018002816A (es) Metodos de tratamiento de mieloma multiple y leucemia de celulas plasmaticas mediante terapia de celulas t.